quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·2d
PRRelease
Corbus Pharmaceuticals Holdings Inc. logo

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

CRBP· Corbus Pharmaceuticals Holdings Inc.
Health Care
Original source

Companies

  • CRBP
    Corbus Pharmaceuticals Holdings Inc.
    Health Care

Recent analyst ratings

  • Jul 30UpdateB. Riley Securities$28.00
  • Feb 28UpdateWilliam Blair-
  • Dec 2UpdatePiper Sandler-
  • Jul 30UpdateWedbush$85.00
  • Jul 22UpdateH.C. Wainwright$80.00
  • Jun 26UpdateB. Riley Securities$85.00

Related

  • SEC7d
    SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.
  • SEC7d
    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • SEC10d
    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR10d
    Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
  • SEC17d
    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR17d
    Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
  • SEC21d
    SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.
  • SEC21d
    SEC Form DEF 14A filed by Corbus Pharmaceuticals Holdings Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022